Method of Treating Urothelial Carcinoma and Other Genitourinary Malignancies Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
AssigneeThe U.S. of America, as represented by the Secretary, Dept. of Health & Human Services
InventorAndrea B. Apolo
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method of treating urothelial carcinoma using Cabozantinib, a kinase inhibitor.
Claims28
A method of treating a cancer selected from the group consisting of urothelial carcinoma, metastatic urothelial carcinoma, urachal adenocarcinoma, squamous cell carcinoma of the bladder, squamous cell carcinoma, urachal adenocarcinoma, castration-resistant prostate cancer, renal cell carcinoma-sarcomatoid tumor, trophoblastic tumor, germ cell cancer, and penile cancer, comprising administering to a patient in need of such treatment Cabozantinib, or a pharmaceutically acceptable salt thereof, in combination with one or more therapeutic agents selected from the group consisting of an anti-CTLA4 monoclonal antibody or an IgG4 anti-PD-1 monoclonal antibody or both an anti-CTLA4 monoclonal antibody and an IgG4 anti-PD-1;
- wherein the structure of Cabozantinib is:
The use of cabozantinib or a pharmaceutically acceptable salt thereof for the treatment of a cancer selected from the group consisting of urothelial carcinoma, metastatic urothelial carcinoma, urachal adenocarcinoma, bladder squamous cell carcinoma of the bladder, castration-resistant prostate cancer, renal cell carcinoma-sarcomatoid tumor, trophoblastic tumor, germ cell cancer, and penile cancer.
The use of a combination of cabozantinib or a pharmaceutically acceptable salt thereof and nivolumab for the treatment of a cancer selected from group consisting of urothelial carcinoma, metastatic urothelial carcinoma, urachal adenocarcinoma, bladder squamous cell carcinoma of the bladder, castration-resistant prostate cancer, renal cell carcinoma-sarcomatoid tumor, trophoblastic tumor, germ cell cancer, and penile cancer.
The use of a combination of cabozantinib or a pharmaceutically acceptable salt thereof and nivolumab and ipilimumab for the treatment of a cancer selected from group consisting of urothelial carcinoma, metastatic urothelial carcinoma, urachal adenocarcinoma, bladder squamous cell carcinoma of the bladder, castration-resistant prostate cancer, renal cell carcinoma-sarcomatoid tumor, trophoblastic tumor, germ cell cancer, and penile cancer.
Dependencies are inferred from the claim text.